Emerald Mutual Fund Advisers Trust’s Xeris Biopharma Holdings XERS Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.2M	Buy	+207,543	New	+$1.38M	0.06%	142

Other funds holding XERS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's XERS Position: Q1 2026 in Review

Emerald Mutual Fund Advisers Trust opened a new position in Xeris Biopharma Holdings (XERS) in Q1 2026: 207,543 shares worth $1.2M. The stake represents 0.06% of the portfolio and ranks #142 among its holdings.

237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

Emerald Mutual Fund Advisers Trust held 207,543 shares of Xeris Biopharma Holdings worth $1.2M as of Q1 2026.
Xeris Biopharma Holdings was a new Emerald Mutual Fund Advisers Trust position in Q1 2026.
Xeris Biopharma Holdings made up 0.06% of Emerald Mutual Fund Advisers Trust's portfolio in Q1 2026, its #142 holding.
237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q1 2026, filed 4 May 2026.